Epitomics, Inc., an emerging biotechnology company, is dedicated to developing proprietary Rabbit monoclonal antibody technology (MAb) to the research and the therapeutic markets.  Its Rabbit monoclonal technology is considered the pioneer in the monoclonal

antibody area and is becoming increasingly popular among end-users.  The company was acquired by Abcam PIc (London: ABC) in April 2012.